Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
March 15, 2023 08:00 ET | Statera Biopharma
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
June 14, 2022 07:30 ET | Statera Biopharma
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing
May 23, 2022 16:05 ET | Statera Biopharma
FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
May 13, 2022 07:30 ET | Statera Biopharma
FORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
April 27, 2022 16:10 ET | Statera Biopharma
FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing
April 22, 2022 17:26 ET | Statera Biopharma
FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
April 13, 2022 16:05 ET | Statera Biopharma
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma, Inc. Files Form 12b-25
March 31, 2022 16:05 ET | Statera Biopharma
FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
March 28, 2022 07:30 ET | Statera Biopharma
Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading...
Final FIle_Statera Biopharma Logo (primary color on white).jpg
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
March 24, 2022 17:28 ET | Statera Biopharma
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...